Abstract:Background The rapid and accurate detection of thyroid-stimulating hormone (TSH) receptor antibodies has always been an urgent need for the clinical diagnosis and management of Graves’ disease (GD). We aimed to evaluate the use of an automated thyroid-stimulating immunoglobulin (TSI) bridge immunoassay in the diagnosis of GD and to analyze the relationship between TSI and the degree of hyperthyroidism. Methods A total of 227 new-onset GD patients, 29 Hashimoto thyroiditis, 43 non-autoimmune thyroid diseases and 37 euthyroid controls were consecutively recruited. All participants accepted the measurement of their serum thyroid function and thyroid-associated antibodies, including TSI being measured by an Immulite 2000 bridge immunoassay and TSH receptor autoantibodies (TRAb) being measured by a third-generation Roche electrochemiluminescence immunoassay. The quantitative consistency between the TSI and TRAb detection methods was analyzed by using Passing-Bablok regression and Bland–Altman plots. The diagnostic performance for GD was assessed by receiver operating characteristic (ROC) curve analysis. Results Among 227 GD patients (174 females and 53 males, with a mean age of 39 years), the quantitative TSI was positively correlated with TRAb ( r = 0.8099). According to the cut-off values proposed by the manufacturers (TSI: 0.55 IU/L, TRAb: 1.75 IU/L), the positive rates of TSI and TRAb in new-onset GD patients were 96.92% and 95.15%, respectively. Both TSI and TRAb levels positively correlated with FT 4 levels (TSI: r = 0.243, TRAb: r = 0.317; all P < 0.001) and FT 3 levels (TSI: r = 0.288, TRAb: r = 0.360; all P < 0.001) in new-onset GD patients. The ROC analysis showed that the optimal TSI cut-off value was 0.577 IU/L for GD diagnosis in this Chinese population, with a sensitivity of 96.92% and a specificity of 97.25%, respectively. The optimal TRAb cut-off value of was 1.38 IU/L, with a sensitivity of 96.92% and a specificity of 99.08%. There were no significant differences between the cut-off values obtained through the ROC analysis and those provided by the manufacturer for both TSI and TRAb when calculating their sensitivity and specificity in diagnosing GD. Among the 8 newly diagnosed GD cases with discordant qualitative antibody results, TSI was more likely than TRAb to match the clinical diagnosis of GD (6 TSI-positive vs. 2 TRAb-positive patients). Conclusion The automated TSI bridge immunoassay was positively correlated with thyroxine levels in new-onset GD patients and was more likely to be consistent with the clinical diagnosis of GD than with that of TRAb. The positive Immulite 2000 TSI cut-off value of 0.577 IU/L for GD diagnosis in the Chinese population were close to the value recommended by the manufacturer.

Profiling of carbonyl metabolic fingerprints in urine of Graves' disease patients based on atmospheric ionization mass spectrometry

Compositional and genetic alterations in Graves’ disease gut microbiome reveal specific diagnostic biomarkers

Ecological and Evolutionary Alterations in Graves’ Disease Gut Microbiome Reveal Specific Diagnostic Biomarkers

Genetically Determined Metabolites in Graves Disease: Insight from a Mendelian Randomization Study.

Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease

GC–MS urinary metabolomics analysis of inherited metabolic diseases and stable metabolic biomarker screening by a comprehensive chemometric method

Identification of Graves' ophthalmology by laser-induced breakdown spectroscopy combined with machine learning method

Identification of two potential biomarkers of Graves' Disease by bioinformatics analyses based on Gene Expression Omnibus datasets with immune cells infiltration.

Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients.

Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry

A Characteristic Biosignature For Discrimination Of Gastric Cancer From Healthy Population By High Throughput Gc-Ms Analysis

Investigating the mechanism and efficacy material basis of Xiehuo Xiaoying decoction for treating Graves' disease via thyroid cell apoptosis based on proteomics and molecular docking techniques

Quantitative profiling of carboxylic compounds by gas chromatography-mass spectrometry for revealing biomarkers of diabetic kidney disease

Intestinal microbiota changes in Graves' disease: a prospective clinical study

MeOx-TMS derivatization for GC-MS metabolic profiling of urine and application in the discrimination between normal C57BL/6J and type 2 diabetic KK-Ay mice

Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves’ disease

Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease

Clinical Evaluation of an Automated TSI Bridge Immunoassay in the Diagnosis of Graves’ Disease and Its Relationship to the Degree of Hyperthyroidism

Chemical Isotope Labeling and Dual-Filtering Strategy for Comprehensive Profiling of Urinary Glucuronide Conjugates

Differential Microrna Expression in Peripheral Blood Mononuclear Cells from Graves' Disease Patients

Evaluation of Analytic and Clinical Performance of Two Immunoassays for Detecting Thyroid‐stimulating Receptor Antibody in the Diagnosis of Graves’ Disease